mynth
← DATABASE
03/2010100%

Care UK acquired by Bridgepoint

UNITED KINGDOM Health Providers / Healthcare Facilities / Nursing Homes EV £300–700M

Context

Bridgepoint acquired 100% of Care UK plc in a public-to-private transaction, taking the company off the public markets to enable a more aggressive growth strategy. The strategic rationale focuses on three pillars: accelerating organic growth, pursuing selective bolt-on acquisitions, and further developing both the social care and NHS healthcare divisions with the support of Bridgepoint's capital and sector expertise. The existing executive management team was retained in full to lead the next phase of Care UK's development, with no changes to front-line care provision.

Care UK, which reported an EBITDA margin of [members only] in 2009, is valued in this transaction at an EV/EBITDA multiple of 5x–12x, to compare with the average currently observed in the Healthcare & Pharma sector (14.3x in 2026).

-> Deep-dive in Healthcare & Pharma market trends

Target

Care UK is one of the UK's largest residential care home chains, founded in 1982 and operating more than 150 homes for older people across the United Kingdom, employing approximately 10,500 staff. Under Bridgepoint's ownership since 2010, the business more than doubled its estate from 59 homes at entry, and fundamentally transformed its revenue mix by increasing the proportion of higher-margin private-pay residents from 5% to over 50%. Care UK is widely recognised as a market leader in care quality, holding the highest number of Outstanding-rated homes in England as assessed by the Care Quality Commission, and achieving 100% compliance in Scotland and Wales.

Ent. Value

£300–700M

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

5x–12x

EV / EBIT

10x–18x

Historical Financials (GBP)

Year
Rev
EBITDA
EBIT
2009
£250–500M
£50–100M
£25–50M
2008
£250–500M
£50–100M
£25–50M

Other operations with Care UK

Other operations with Care UK
DateAcquirerTargetCountrySector
11/2024WELLTOWERCARE UKUNITED KINGDOMNursing Homes

Other operations with Bridgepoint

Other operations with Bridgepoint
DateAcquirerTargetCountrySector
10/2026BRIDGEPOINTLANSWEEPERBELGIUMSoftware
09/2026BRIDGEPOINTVIPR SOLUTIONSUNITED KINGDOMData, Analytics & AI
09/2026BRIDGEPOINTALTANOGERMANYVet Clinics
07/2026BRIDGEPOINTGBA GROUPGERMANYTIC (Testing, Inspection, Certification)
07/2026BRIDGEPOINTSKELLOFRANCEERP, HR & Finance
07/2026BRIDGEPOINTUMAG SOLUTIONSDENMARKElectronics
06/2026BRIDGEPOINTOBAGI MEDICALUNITED STATESGenerics / Labs
06/2026BRIDGEPOINTKAYNE ANDERSON REAL ESTATEUNITED STATESWealth & Asset Management
02/2026BRIDGEPOINT / POLARIS PRIVATE EQUITYPDSVISION GROUPSWEDENConsulting & Integration
01/2026BRIDGEPOINTINTERPATHUNITED KINGDOMAccounting & Audit

Similar deals in Health Providers

Similar deals in Health Providers
DateAcquirerTargetCountrySector
01/2015CERBA HEALTHCARENOVESCIAFRANCELabs (Biology)
10/2014WATERLANDMEDIAN KLINIKENGERMANYClinics / Hospitals
09/2014EURAZEOCOLISÉEFRANCENursing Homes
06/2014PAI PARTNERSDOMUSVIFRANCENursing Homes
03/2014EQT PARTNERSI-MED RADIOLOGY NETWORKAUSTRALIARadiology
07/2012MANAGEMENT & PRIVATE INVESTORSLVL MEDICAL GERMANYGERMANYOutpatient Care
06/2012AIR LIQUIDEORKYN (EX LVL MEDICAL)FRANCEOutpatient Care
12/2010SAGA GROUPNESTOR HEALTHCARE GROUPUNITED KINGDOMOutpatient Care
06/2010PAI PARTNERSCERBA HEALTHCAREFRANCELabs (Biology)
05/2010HG CAPITALFRÖSUNDASWEDENHealthcare Facilities

REFERENCES

Valuation range: EV £300–700M

Revenue range: £250–500M

EBITDA range: £50–100M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 5x - 12x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Care UK by Bridgepoint are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: bridgepoint

FAQ

What transaction does this page cover?

This page covers Bridgepoint’s acquisition of 100% of Care UK, a British company specialised in Healthcare Facilities, in 2010. Ownership has since evolved, leading to a subsequent transaction with Welltower in November 2024 (see the dedicated deal page for details).

How was the acquisition of Care UK by Bridgepoint valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the £300–700M band, its EV/EBITDA multiple within the 5x - 12x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Care UK’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Care UK generated annual revenue estimated in the £250–500M range and EBITDA in the £50–100M bracket (FY 2009). Detailed financial figures are available to members.

How does the valuation of Care UK compare to benchmarks in the Healthcare & Pharma sector?

With an estimated valuation multiple in the range of 5x - 12x in 2010, the transaction reflects historical valuation standards. By way of comparison, in 2026 companies in the Healthcare & Pharma sector are valued at a multiple of 14.3x EBITDA.

What sources support the information on this transaction?

Information on this transaction is supported by three corroborating sources: an official corporate announcement published by the parties, independent reporting from specialized financial publications, as well as a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.